BioNTech faces a pivotal moment in its corporate evolution as two major developments converge, testing the company’s strategic direction and market confidence. The German biotech firm navigates simultaneous challenges that could redefine its future trajectory.
Shareholder Vote Looms for CureVac Takeover
A critical decision awaits CureVac investors on November 25, 2025, when they will determine the fate of BioNTech’s proposed €1.25 billion acquisition. The all-stock transaction requires approval from 75-80% of CureVac shareholders, who would receive approximately $5.46 per share in BioNTech stock. The final exchange ratio incorporates a collar mechanism tied to BioNTech’s share price, introducing valuation uncertainty into the proceedings.
This potential merger would consolidate two significant mRNA technology platforms under BioNTech’s umbrella. The path cleared earlier in 2025 when CureVac resolved patent disputes with both Pfizer and BioNTech, removing a substantial obstacle to the combination. Successfully integrating CureVac could substantially enhance BioNTech’s technological assets and manufacturing capabilities.
Pfizer’s Potential Exit Raises Questions
Amid this delicate acquisition phase, Bloomberg reported on November 13 that Pfizer is considering divesting its remaining BioNTech stake, valued at up to $508 million. The pharmaceutical giant reportedly offered approximately 4.55 million American Depositary Receipts at prices between $108 and $111.70 each.
BioNTech responded promptly with assurances about the “close and strong collaboration” with Pfizer but refrained from commenting specifically on its partner’s market activities. While the operational cooperation on COVID-19 vaccine development continues, the news triggered a 5% pre-market decline in BioNTech shares, reflecting investor concerns about the partnership’s stability.
Should investors sell immediately? Or is it worth buying BioNTech?
Quarterly Performance: Mixed Signals
BioNTech’s third-quarter 2025 results, released November 3, presented a complex financial picture. Revenue reached €1.52 billion, substantially exceeding analyst projections of €1.01 billion. This performance was primarily driven by a $1.5 billion payment from Bristol Myers Squibb as part of a collaboration agreement.
However, the company reported a quarterly loss of €0.12 per share, contrasting with expert expectations of a €0.10 profit. BioNTech raised its full-year 2025 revenue guidance to €2.6-2.8 billion, up from the previous €1.7-2.2 billion range, while simultaneously planning reductions in research and administrative expenses. With €16.7 billion in liquid assets, the company maintains substantial resources to support its transition from COVID-19 vaccine specialist to diversified oncology enterprise.
Oncology Pipeline Encounters Delays
BioNTech’s strategic pivot toward cancer therapeutics shows promising early results but faces scheduling setbacks. Positive interim data emerged for pumitamig (BNT327), a bispecific antibody targeting small cell lung cancer. Nevertheless, several clinical trials have experienced timeline adjustments:
- Phase 3 trial for triple-negative breast cancer postponed to late 2025
- BNT122 Phase 2 update for colorectal cancer delayed until early 2026
- BNT323 regulatory submission pushed to 2026
In response to these developments, TD Cowen reduced its price target from $120 to $116 while maintaining a “Hold” rating.
Critical Juncture for Future Direction
BioNTech operates from a position of financial strength but confronts significant strategic challenges. The CureVac shareholder decision could establish the foundation for a more comprehensive mRNA platform, while the company must recalibrate its relationship with Pfizer. With more than 20 ongoing Phase 2 and Phase 3 oncology trials, BioNTech has placed substantial bets on diversifying beyond its COVID-19 legacy. The ultimate success of this strategy depends heavily on accelerating clinical development timelines and the outcome of the November 25 shareholder vote.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from November 18 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 18.
BioNTech: Buy or sell? Read more here...
